Bioequivalence of high variation drug abiraterone acetate tablets in healthy subjects

doi:10.12092/j.issn.1009-2501.2018.10.009

Abstract

Abstract:

AIM: To evaluate the bioequivalence of the experimental preparation and reference preparation of the high-variation drug abiraterone acetate tablets administered once orally in the healthy Chinese volunteers after taking fatty food. METHODS: It was a randomized, open-label, double- sequence, four-period, repeated cross-test and 32 healthy volunteers were given a single oral 250 mg dose of test or reference abiraterone acetate tablets with a high-fat meal. The blood concentrations of abiraterone in plasma were determined by LC-MS/MS. The major pharmacokinetic parameters were calculated with the aid of WinNonlin 7 and the bioequivalence was evaluated. RESULTS:The abiraterone's major pharmacokinetic parameters of test and reference were as follows: C _max were（238.0±108.6）and（220.1±96.9）ng/mL; T _maxwere 2.0 (1.0-4.0) and 2.0 (1.0-5.0) h; t _1/2 were (13.1±2.6) and (13.0±2.9) h; AUC _0-t were (615.2±226.3) and (589.4±210.1) h·ng·mL^-1， AUC _0-∞ were (618.7±227.7) and (592.8±211.6) h·ng·mL^-1, respectively. The 90% confidence interval, the geometric mean ratio（T/R）of the AUC _0-t ,AUC _0-∞ and C _max, all ranged from 80.00% to 125.00%. CONCLUSION: The test preparation of acetabone acetate tablets is bioequivalent to the reference preparation after diet.

Key words: abiraterone acetate, healthy volunteers, bioequivalence, LC-MS/MS

CLC Number:

R969

LIU Yanan, YANG Guoping, PEI Qi, WANG Yiya, JIAO Feifei, YANG Xiaoyan, YANG Shuang, GUO Can, HUANG Jie. Bioequivalence of high variation drug abiraterone acetate tablets in healthy subjects[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1141-1146.

References

［1］Chen W, Zheng R, Baade PD, et al. Cancer Statistics in China, 2015［J］. CA Cancer J Clin，2016，66(2): 115-132.
［2］陈鸿杰, 王民三.醋酸阿比特龙治疗去势抵抗性前列腺癌的研究进展［J］.国际泌尿系统杂志, 2015, 35(3): 437-439.
［3］周爱萍,房虹,李长岭,等. 去势抗拒前列腺癌治疗新药醋酸阿比特龙［J］. 中国新药杂志,2013,22(17):1998-2001.
［4］Caffo O, Veccia A, Kinspergher S，et al. Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review［J］. Future Oncol，2018, 14(5):431-442.
［5］吴开杰，介评.New England Journal of Medicine:阿比特龙在转移性激素敏感性前列腺癌中的应用---LATITUDE试验中期结果发布［J］. 现代泌尿外科杂志, 22 (8) :630-630.
［6］孙颖浩,杨悦.前列腺癌内分泌治疗的现状与展望［J］.实用医院临床杂志, 2017 , 14 (6) :1-4.
［7］刘琪,刘明,朱刚,等. 转移性去势抵抗性前列腺癌药物治疗进展［J］. 现代泌尿外科杂志,2014,19(9):625-627.
［8］Fizazi K, Scher HI, Molina A. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study［J］. Lancet Oncol,2012，13(10):983-392.
［9］Draft Guidance on Abiraterone Acetate, FDA［DB/OL］.https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM333001.pdf Accessed Jan 2016
［10］Inoue K, Shishido A, Vaccaro N, et al.Pharmacokinetics of abiraterone in healthy Japanese men:dose-proportionality and effect of food timing［J］. Cancer Chemother Pharmacol, 2015, 75(1):49-58.
［11］Chi KN，Spratlin J,Kollmannsberger C，et al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer［J］. J Clini Pharma, 2015, 55(12): 1406-1414.
［12］Gomez L, Kovac JR, Lamb DJ. CYP17A1 inhibitors in castration-resistant prostate cancer［J］. Steroids, 2015 , 95 :80-87.
［13］EMA/CHMP/542871 (2011) Assessment report for Zytiga procedure no.: EMEA/H/C/002321［R］. Assessment, vol. 44.
［14］Geboers S, Stappaerts J, Mols R, et al. The effect of food on the intraluminal behavior of abiraterone acetate in man［J］. J Pharm Sci, 2015,105(9):2974-2981.
［15］王晶，阳国平，黄洁，等, 醋酸阿比特龙片在中国健康受试者的药代动力学和生物等效性研究［J］. 中国临床药理学杂志, 2018,34(16): 1989-1992.

[1]	YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177.
[2]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[3]	LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HUANG Kai. Safety analysis on bioequivalence studies of orally inhaled drug products in healthy Chinese subjects#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1131-1138.
[4]	GU Yifei, CHU Nannan, HUANG Kai, QUE Linling, ZHANG Jisheng, XIANG Xuemei, HE Qing. Application and progress of pharmacodynamics study in bioequivalence evaluation of orally inhaled drug products [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 822-833.
[5]	WU Juan, WANG Zhiqiang, ZHOU Renpeng, YANG Jingjing, QIN Huiling, ZHANG Qian, LU Chao, HU Wei. Bioequivalence trial of fasting oral sorafenib tosylate tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 281-286.
[6]	SHI Gexin, CHONG Rui, HE Kun, WU Haitang, ZHOU Yu, DUN Zhongjun, WEN Qing, ZHANG Jiguo, ZHANG Rong. A fully replicated crossover bioequivalence study of mycophenolate mofetil capsules in Chinese healthy male subjects under fasting and fed conditions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1255-1263.
[7]	GAO Rong, MA Yazhong, ZHAO Haixia, WANG Zhaoyuan, ZHANG Weihong, YUAN Hailong. Bioequivalence of amlodipine besylate tablets in Chinese healthy subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 56-62.
[8]	HU Yin, YANG Dandan, XU Yichao, SHAO Rong, RUAN Zourong, JIANG Bo, CHEN Jinliang, LOU Honggang. Application of artificial neural network model in bioequivalence study of candesartan cilexetil tablets [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 63-69.
[9]	CAI Mingmin, SHAO Jing, TANG Lu, SUN Qiuyue, DOU Ting, QIAN Wei, WANG Huiping. Bioequivalence study of buthlphthalide injection in Chinese healthy volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 70-76.
[10]	ZHENG Binjie, LIU Na, ZENG Xiangchang, HUANG Xinyi, CHEN Lulu, OU-YANG Dongsheng. Effects of gut microbiota on pharmacokinetics and its consideration in the evaluation of the consistency of quality and efficacy of generic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 662-671.
[11]	SUN Yuchen, LIU Yinhui, ZHANG Xian, YUAN Tong, JING Mengyao, ZAHNG Xinyu, YANG Jin. Exploration of screening criteria for healthy volunteers in human bioequivalence clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 714-720.
[12]	XU Guofang, ZHANG Sisen, LIU Ping, MEI Jiazhuan, LIU Weiwei, LIU Ya'ou, QI Qi. Population pharmacokinetics of capecitabine in Chinese breast cancer patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 552-559.
[13]	MA Hong, LIU Jingyuan, JIN Hao, CHEN Yong, WANG Bo, LIU Wanhui, SI Duanyun, XIA Yuanyuan. Quantification of ambrisentan in human plasma by LC-MS/MS and its pharmacokinetic application [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 382-388.
[14]	LI Xiaomin, JIN Hao, ZHOU Wenzhi, YANG Hanyue, ZOU Ting, GUO Jie, XU Pingsheng. Bioequivalence of metformin hydrochloride sustained-release tablets in healthy subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 408-413.
[15]	WANG Hui, CUI Chang, YANG Shuang, YAO An, WU Shuting, YANG Xiaoyan, YE Ling, ZOU Zhi, TANG Zhi, YANG Guoping, HUANG Jie, OUYANG Dongsheng. Bioequivalence of solifenacin succinate tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 299-304.